2. Academic Validation
  3. Discovery of 2-Pyridylpyrimidines as the First Orally Bioavailable GPR39 Agonists

Discovery of 2-Pyridylpyrimidines as the First Orally Bioavailable GPR39 Agonists

  • ACS Med Chem Lett. 2014 Aug 4;5(10):1114-8. doi: 10.1021/ml500240d.
Stefan Peukert 1,  Richard Hughes 1,  Jill Nunez 1,  Guo He 1,  Zhao Yan 1,  Rishi Jain 1,  Luis Llamas 1,  Sarah Luchansky 1,  Adam Carlson 1,  Guiqing Liang 1,  Vidya Kunjathoor 1,  Mike Pietropaolo 1,  Jeffrey Shapiro 1,  Anja Castellana 1,  Xiaoping Wu 1,  Avirup Bose 1
Affiliations

Affiliation

  • 1 Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
PMID: 25313322 DOI: 10.1021/ml500240d
Abstract

The identification of highly potent and orally bioavailable GPR39 agonists is reported. Compound 1, found in a phenotypic screening campaign, was transformed into compound 2 with good activity on both the rat and human GPR39 receptor. This compound was further optimized to improve ligand efficiency and pharmacokinetic properties to yield GPR39 agonists for the potential oral treatment of type 2 diabetes. Thus, compound 3 is the first potent GPR39 agonist (EC50s ≤ 1 nM for human and rat receptor) that is orally bioavailable in mice and robustly induced acute GLP-1 levels.

Keywords

GLP-1 secretion; GPR39 agonists; GPR39 receptor; Zn2+-sensing receptor; antidiabetic treatment; insulin secretion; β-cell protection.

Figures
Products